In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy
Journal of Extracellular Vesicles · 2026-01 · 15 (1)
DOI: 10.1002/jev2.70222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 06.01.2026. Verfasst von Tianye Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Immunotherapy, Oncolytic Viruses, Oncolytic Virotherapy, Adenoviridae. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Liaoning Revitalization Talents Program, The Outstanding Youth lifting Program in the Shenyang Pharmaceutical University.
Abstract (Originalsprache)
Oncolytic adenoviruses (OVs) can directly eliminate cancer cells and subsequently activate immune responses, exhibiting potent antitumor therapeutics. However, it was observed that the immune cells can also be lysed during viral treatment, evidently dampening the OVs‐mediated antitumor immune response. In this study, we develop a microneedle (MN)‐based in situ tumor cell‐derived extracellular nanovesicle (TDEV)‐cloaked OVs platform to enhance cancer immunotherapy and reduce immune cell exhaustion. In this platform, tumor cells pre‐infected with OVs are loaded into the upper reservoir of the MN device. Following the transdermal administration, the hollow MN would constantly facilitate the transport of in situ the generated TDEV‐encapsulating OVs into the tumor site for sustained delivery of OVs, which could subsequently infect cancer cells selectively rather than immune cells. Enhanced antigens triggered by improved intratumoral OVs killing can be presented by non‐exhausted dendritic cells, further evoking significant immunotherapeutic effects in both TC‐1‐hCD46 xenograft tumor‐bearing mice and postoperative tumor recurrence mice models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China.
- Department of General Surgery, The First Hospital of Dalian Medical University, Dalian, China.
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal tumors, China Medical University, Ministry of Education, Shenyang, China.
- State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou, China.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
- Joint International Research Laboratory of Intelligent Drug Delivery Systems Ministry of Education, Shenyang, China.
ORCID-Profile: Jin Sun
Förderung
- National Key Research and Development Program of China
- Liaoning Revitalization Talents Program
- The Outstanding Youth lifting Program in the Shenyang Pharmaceutical University
- National Natural Science Foundation of China
Zitieren
APA
Wang, T., Zhao, S., Ji, Z., He, Z., Cheng, Z., Gu, Z., Zhang, Y., Sun, J., Liu, F., & Sun, M. (2026). In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy. Journal of Extracellular Vesicles, 15(1). https://doi.org/10.1002/jev2.70222
Vancouver
Wang T, Zhao S, Ji Z, He Z, Cheng Z, Gu Z, et al. In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy. Journal of Extracellular Vesicles. 2026;15(1). doi:10.1002/jev2.70222
BibTeX
@article{Wang2026,
author = {Wang, Tianye and Zhao, Sheng and Ji, Zao and He, Zhonggui and Cheng, Zhenguo and Gu, Zhen and Zhang, Yuqi and Sun, Jin and Liu, Funan and Sun, Mengchi},
title = {In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy},
journal = {Journal of Extracellular Vesicles},
year = {2026},
volume = {15},
number = {1},
doi = {10.1002/jev2.70222}
}
EUVIMED